ArticleNeurocritical care2015
Augmented Renal Clearance in Patients with Subarachnoid Hemorrhage.
Article in Neurocritical care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury
Augmented Renal Clearance in Neurocritical Care Population: A Prospective Multicenter Study
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines for Seizure Prophylaxis in Patients with Aneurysmal Subarachnoid Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society.Neurocritical care · 2026Guideline
- Brain-kidney crosstalk in subarachnoid hemorrhage patients.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2026Article
- Prospective evaluation of individualized vancomycin dosing based on a population pharmacokinetic model in patients with severe Gram-positive bacterial infection.Frontiers in pharmacology · 2026Article
- Levetiracetam Dosing Optimization in Neurocritical Care Population: Neuro-ARC Study.Neurocritical care · 2025Observational
- The Impact of Augmented Renal Clearance on the Pharmacokinetics of Levetiracetam in Critically Ill Patients: A Literature Review.Journal of clinical pharmacology · 2025Review
- Prevalence and Risk Factors for Augmented Renal Clearance in Neurocritical Ill Patients.Journal of clinical laboratory analysis · 2025Observational
- Augmented Renal Clearance: Prevalence, Risk Factors and Underlying Mechanism in Critically Ill Patients with Subarachnoid Hemorrhage.Neurocritical care · 2025Article
- Beta-Lactam Antibiotic Concentrations and the Acquisition of Multi-Drug Resistant Bacteria in Critically Ill Patients.Life (Basel, Switzerland) · 2025Article
- Intestinal Drug Absorption After Subarachnoid Hemorrhage and Elective Neurosurgery: Insights From Esomeprazole Pharmacokinetics.Critical care medicine · 2025Observational
- Augmented renal clearance in neurocritical patients: An epidemiological investigation and risk-factor analysis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- Enhanced renal clearance impacts levetiracetam concentrations in patients with traumatic brain injury with and without augmented renal clearance.BMC neurology · 2024Article
- Creatinine Clearance in Acute Brain Injury: A Comparison of Methods.Neurocritical care · 2023Observational
- Measured Creatinine Clearance: Still a Good Surrogate of Glomerular Filtration Rate in Neurocritically Ill Patients!Neurocritical care · 2023Article
- Augmented Renal Clearance in Patients with Acute Ischemic Stroke: A Prospective Observational Study.Neurocritical care · 2023Observational
- Prevalence and prediction of augmented renal clearance in the neurocritical care population.Journal of neurocritical care · 2022Article
- Risk factors associated with augmented renal clearance in a mixed intensive care unit population: a retrospective study.International journal of clinical pharmacy · 2022Observational
- Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue.Antimicrobial agents and chemotherapy · 2022Article
- Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study.Journal of intensive care · 2022Article
- Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis.Pharmaceutics · 2022Review
- Augmented Renal Clearance in Severe Infections-An Important Consideration in Vancomycin Dosing: A Narrative Review.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPatients with subarachnoid hemorrhage (SAH) typically exhibit hyperdynamic cardiovascular hemodynamics, which may lead to increased medication clearance. The aims of this study were to evaluate the actual creatinine clearance (CrClA) in an aneurysmal SAH population and the effect of the development of cerebral vasospasm (CV) along with its treatment to better understand if this population exhibits augmented renal clearance (ARC).
methodsThis was a prospective, single-center study in a neurosciences ICU at a university hospital. A total of 20 patients were consented and provided a 24-h urine sample to measure the CrClA. If patients experienced CV, a 24-h urine collection was repeated during vasospasm treatment. CrClA was measured using a modified Jaffe assay.
resultsAmong the 20 patients enrolled, the mean SAH CrClA was 325.93 ± 135.20 ml/min 1.73 m(2) and this differed significantly from the SAH estimated creatinine clearance (CrClE) 144.93 ± 42.82 ml/min 1.73 m(2) (p < 0.001). Four patients developed CV; the mean CV CrClA was 558.43 ± 356.12 ml/min 1.73 m(2) and there was no significant difference when compared to those patients' mean SAH CrClA (246.91 ± 84.14 ml/min 1.73 m(2), p = 0.16).
conclusionsARC was present in 100 % of the patients with recent SAH enrolled. Although ARC remained present in the patients who experienced CV, their creatinine clearance was not significantly further augmented. Further work is needed to clarify the impact of such clearances on renally excreted medications and how the development and treatment of CV further augment these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.